NCT01728740View on ClinicalTrials.gov

Bioequivalence Study for Acarbose / Metformin FDC

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Diabetes Mellitus, Type II
Interventions
DRUG

Acarbose/Metformin FDC (BAY81-9783)

Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose

DRUG

Acarbose (Glucobay, BAYG5421)

Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose

DRUG

Metformin

Metformin 500mg, oral, single dose

Trial Locations (1)

110-744

Seoul

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01728740 - Bioequivalence Study for Acarbose / Metformin FDC | Biotech Hunter | Biotech Hunter